From GlobeNewswire: 2025-03-25 16:05:00

Climb Bio, Inc. received FDA clearance for clinical trials of Budoprutug in pMN, ITP, and SLE. They completed studies for process optimization and filed patents. The company expanded its pipeline to include CLYM116 for IgAN. Perrin Wilson, Ph.D., was appointed as Chief Business Officer. Financially, the company ended 2024 in a strong position with cash expected through 2027.

In 2024, Climb Bio rebranded and focused on bringing medicines to immune-mediated disease patients. Budoprutug is a key asset for pMN, ITP, and SLE. They also licensed CLYM116 for IgAN. The company’s financial results showed a strong cash position. Climb Bio aims to advance new treatment options for the millions living with immune-mediated diseases in the U.S.

Recent highlights for Climb Bio include FDA clearance for Budoprutug in pMN and ITP trials, completion of studies for process optimization, and expansion of the pipeline to include CLYM116 for IgAN. Perrin Wilson, Ph.D., was appointed as Chief Business Officer. The company ended 2024 in a strong financial position with cash expected through 2027.



Read more at GlobeNewswire:: Climb Bio Reports Fourth Quarter and Year-End 2024